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1,3-Butadiene (BD), a volatile organic chemical (VOC), is used in synthetic rubber production and other
industrial processes. It is detectable at low levels in ambient air as well as in tobacco smoke and gasoline
vapors. Inhalation exposures to high concentrations of BD have been associated with lung cancer in both
humans and experimental animals, although differences in species sensitivity have been observed.
Metabolically active lung cells such as Pulmonary Type I and Type II epithelial cells and club cells
(Clara cells)1 are potential targets of BD metabolite-induced toxicity. Metabolic capacities of these cells,
their regional densities, and distributions vary throughout the respiratory tract as well as between species
and cell types. Here we present a physiologically based pharmacokinetic (PBPK) model for BD that includes
a regional model of lung metabolism, based on a previous model for styrene, to provide species-dependent
descriptions of BD metabolism in the mouse, rat, and human. Since there are no in vivo data on BD pharma-
cokinetics in the human, the rat and mouse models were parameterized to the extent possible on the basis
of in vitro metabolic data. Where it was necessary to use in vivo data, extrapolation from rat to mouse was
performed to evaluate the level of uncertainty in the human model. A kidney compartment and description
of downstream metabolism were also included in the model to allow for eventual use of available urinary
and blood biomarker data in animals and humans to calibrate the model for estimation of BD exposures and
internal metabolite levels. Results from simulated inhalation exposures to BD indicate that incorporation of
differential lung region metabolism is important in describing species differences in pulmonary response
and that these differences may have implications for risk assessments of human exposures to BD.
 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CCBY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
1,3-Butadiene (BD)2 (CAS No. 106-99-0) is a colorless and mildly
aromatic gas. It is commonly used in the manufacturing of tires,shoes, sponges, hoses, luggage, and a variety of molded products
[61]. BD is also a constituent of tobacco smoke, gasoline vapors,
and vapors from the burning of plastics and rubber, and has been
detected at low part-per-billion levels in outdoor air [43]. BD is aCrowell),
clewell@
lls in this
ne; CYP,
ene; EH,
maximal
er rate of
L, Paciﬁc
J. Campbell et al. / Chemico-Biological Interactions 238 (2015) 102–110 103known human carcinogen [23] and has been associated with cancer
in multiple sites [19], as well as non-carcinogenic outcomes, notably
reproductive toxicity in animals [11]. Studies have shown that mice
are much more sensitive to BD toxicity than rats, due at least in part
to species-speciﬁc kinetic differences between rats and mice, and
differences between mice and humans [19]. The carcinogenicity
and toxicity observed from BD exposure have been attributed to
its epoxide metabolites, 1,2-epoxy-3-butene (epoxybutene, EB) and
1,2,3,4-diepoxybutane (DEB).
BD is activated primarily by cytochrome P450 2E1 (CYP 2E1) to
produce the genotoxic metabolites EB and DEB [1,6,29]. These
reactive epoxide metabolites can form hemoglobin adducts and
are believed to be responsible for BD-induced genotoxicity and car-
cinogenicity, as well as the non-carcinogenic effects. EB is then fur-
ther metabolized by three different pathways: conjugation by
glutathione-S-transferase (GST) to form the urinary metabolite
M2 (an isomeric mixture of 1-hydroxy-2-(N-acetylcysteinyl)-3-b
utene and 2-hydroxy-1-(N-acetylcysteinyl)-3-butene), hydrolyza-
tion by epoxide hydrolase (EH) to 1,2-dihydroxy-3-butene
(epoxybutanediol, BD-diol), and ﬁnally oxidation to the more
genotoxic metabolite, DEB, by cytochrome P450 (Fig. 1).
BD-diol is further metabolized in multiple steps by alcohol
dehydrogenase, aldehyde dehydrogenase, and cytochrome P450
to form the intermediate hydroxymethylvinyl ketone (HMVK),
which is then further conjugated by GST to form the urinary
metabolite, M1 (1,2-dihydroxy-4-(N-acetylcysteinyl)-butane).
In addition to the liver, the lung and kidney have been shown
to be sites of BD metabolism, as well as target sites for tissue
damage and carcinogenicity in rodents [12,26,56]. In pulmonary
tissues, epithelial cells (Pulmonary Type I and Type II) and club
cells (based on the suggestions in Winkelmann and Noack
(2010) [63] and Irwin et al. (2013) [25], bronchiolar exocrine cells
or Clara cells will be referred to as club cells) are the primary
metabolically active cells and potential targets of BD epoxide
metabolite-induced toxicity and carcinogenicity [19]. However,Fig. 1. A simpliﬁed metabolic scheme for BD showing the metabolism modeled. A box aro
lines indicate planned additions to the model. EH – epoxide hydrolase, GST – glutathione-
that are not referenced in this simpliﬁed scheme.metabolic capacities, regional densities, and the distribution of
these cells vary throughout the respiratory tract and across differ-
ent species [55].
In mice, metabolically active cells can be found at all levels of
the respiratory tract [49,46,45,51], while in rats and humans they
are conﬁned to the transitional airways immediately before the
alveolar regions of the lung [47,51,42]. This, along with the
increased rates of metabolic activation of BD in the respiratory tis-
sues of mice [12,16,56,7,15,38,36,35], may be the reason for the
greater susceptibility of mice, compared to rats, to BD-induced pul-
monary toxicity and carcinogenicity [19]. Therefore, it is important
to include a more complex description of the respiratory tract in a
PBPK model to adequately account for the species-speciﬁc differ-
ences and the complex activation of BD in the lung.
Numerous PBPK models for BD and its metabolites have been
developed and are available in the published literature
(Table A-1) [28,40,13,34,59]. However, the existing BD inhalation
PBPK models treat the lung as a homogenous organ with metabo-
lism occurring evenly throughout, despite known differences in
lung physiology and metabolic capacity across respiratory regions
and between species. Therefore, these models insufﬁciently eluci-
date species-speciﬁc differences in the lung metabolism of BD to
support cross-species extrapolation of lung cancer risk.
The aim of the BD PBPKmodel presented here for mice, rats, and
humans is to more accurately model inhalation exposure to BD
using an expanded description of the lung compartment ﬁrst used
for styrene [55]. The model described here distributes the metabo-
lism to speciﬁc sub-divided regions with distinct metabolic charac-
teristics – oral/nasal passage, conducting airways (trachea,
bronchi, and anterior bronchioles), transitional airways (terminal
bronchioles), and the alveolar gas exchange region – and provides
the capability to estimate region-speciﬁc dosimetry. The model
also includes a more detailed and complex description of metabo-
lism of BD by the inclusion of a kidney compartment and metabo-
lite sub-models, which will allow for consideration of availableund the chemical structure indicates it is a reactive epoxide metabolite, and broken
S-transferase, P450 – cytochrome P450. Note: there are multiple urinary metabolites
Fig. 2. Basic structure of PBPK model for BD and its major metabolite, epoxybutene (EB). Additional metabolites are also modeled but not shown explicitly. In the mouse,
metabolically active cells are distributed in both the conducting and transitional airways, but in humans and rats, they are present only in the transitional airways.
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tion and will more accurately describe the metabolism of BD.2. Methods
2.1. PBPK model structure
The inhalation PBPK model for BD was written in acslX (version
3.0, Aegis Corporation, Huntsville, AL, USA). The Gear algorithm
was used for integration of double precision variables. The PBPK
model contains seven compartments representing the liver, kid-
ney, fat, richly perfused tissues, slowly perfused tissues, oral/nasal
cavity, and multi-compartment lung, connected via arterial and
venous blood (Fig. 2).
Sub-models of EB and BD-diol were also included to track the
metabolism of BD. The lung compartment was divided into four
main regions – the nasal cavity, conducting airways, transitional
airways, and the alveolar gas exchange region. With the exception
of the nasal cavity, each level of the respiratory tract is separated
into the lumen, epithelial cells, and submucosa tissues (Fig. 3).
The nasal cavity airways are comprised of the lumen and nasal tis-
sue. Cytochrome P450 metabolism in the lung is limited to certain
epithelial cells: Type I, Type II, and club cells [51]. A complete
description of the respiratory architecture employed in this PBPK
model can be found in Sarangapani and Teeguarden [55].
The metabolic description was based on that described in previ-
ous BD model efforts [33,34,28,58]. Metabolism in the pulmonary
region was isolated to the transitional airway as this is the primary
site of metabolically active cells in human respiratory tract
[47,51,42]. The model also includes a metabolically active kidney
compartment to account for the metabolism of EB and BD-diol to
the urinary metabolites M1 and M2, respectively [34,59]. The oxi-
dation of BD and EB by cytochrome P450 (CYP) in the liver, kidney,
and transitional airway is described as a saturable process (Vmax
and Km) and includes competitive inhibition, as described in
Kohn and Melnick [33]. The hydrolysis of EB by epoxide hydrolase
(EH) is also described as a saturable process in the liver, kidney,
and metabolically active areas of the lung. The ‘‘privileged access’’
description of Kohn and Melnick [33] was used in the liver, where
colocation of the EH enzyme with the CYP enzyme results in access
to metabolism prior to EB being available for partitioning toplasma. The release of bound EB (KRELEB) was adjusted to mini-
mize the ratio of AUC calculated within the time of measured data
(i.e., 120 min to ﬁnal sample for plasma and 180 min to ﬁnal sam-
ple time for lung) between observed and simulated EB in plasma
and lung for rat. A similar rate constant of 1.4 min1 provided
acceptable ﬁts to the mouse and was retained for the human.
Conjugation of EB is modeled in the liver, relevant airways, and
the kidney, and occurs by a ping–pong mechanism [28,13]. The
rate equation for GSH level (RAgshT) is described as:
RAgshT ¼ kPgshT kEgsh  VT  CgshT RAMTgsh
where kPgshT is the tissue-speciﬁc zero-order rate of GSH synthesis
(determined from basal tissue GSH concentrations and the basal
elimination rate), kEgsh is the ﬁrst-order rate of basal GSH elimina-
tion, VT is the tissue volume, CgshT is the tissue concentration of
GSH, andRAMTgsh is the rate of conjugationofGSHandEB. This same
method was also used to describe the conjugation of the BD-diol
intermediate HMVK to the urinary biomarker, M1. BD-diol is also
modeled through saturable oxidation in the liver, kidney, and in only
the conducting airway and transitional airway of the lung, by cyto-
chrome P450 to form the intermediate HMVK, which is further con-
jugated to produce M1 in the urine (as discussed earlier).
Physiological, biochemical, and metabolic parameters used in
the model are listed in Tables A-2 to A-4 for rats, mice, and
humans, respectively. Metabolic parameters for the mouse and
rat (Table A-4) were taken from Kohn and Melnick [33], Sweeney
et al. [59], and Johanson and Filser [28] and are based on metabolic
rates from in vitro studies of BD and EB metabolism in mouse and
rat microsomes. The rate constants for humans (Table A-4) were
derived from in vitro measurements reported in Csanády et al.
[12] and employed by Sweeney et al. [59] or set to the rat value
for pathways that were not assessed in human microsomal prepa-
rations. In keeping with the Kohn and Melnick [33,34] description,
maximum rates of metabolism for the saturable processes were
scaled to the tissue using the tissue-speciﬁc concentration of
microsomal or cytosolic protein per gram of tissue [66].
2.2. Data used for model parameters
A search of the published literature, using the PubMed biblio-
graphic database, was performed to identify studies containing
Fig. 3. Detail of the structure used to model the transitional airways.
Fig. 4. BD concentrations in the blood of B63CF1 mice (top) or Sprague-Dawley rats
(bottom) during and following six hours of inhalation exposure to a target
concentration of 62.5 ppm, 625 ppm or 1250 ppm of BD (71 ppm, 603 ppm, or
1282 ppm in mice and 63 ppm, 616 ppm, or 1249 ppm in rats; observed data from
[18]).
Fig. 5. EB in the blood of B63CF1 mice (top) or Sprague-Dawley rats (bottom)
during and following six hours of inhalation exposure to a target concentration of
62.5 ppm, 625 ppm or 1250 ppm of BD (71 ppm, 603 ppm, or 1282 ppm in mice and
63 ppm, 616 ppm, or 1249 ppm in rats; observed data from [18]).
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rat, or human urine and metabolic rate data for BD metabolites in
the kidney, lung, and liver. Tables A-1 to A-4 summarize the rele-
vant information identiﬁed from the literature search results that
were used in the parameterization of the model for the mouse,
rat, and human. Tissue volumes were scaled linearly with body
weight, cardiac output was scaled as body weight to the 0.75
power, and tissue perfusion rates were set as a fraction of cardiac
output. Partition coefﬁcients and hepatic metabolic rate constants
were taken from the literature. Parameters describing the structure
of sub-compartments of the lung (lumen, volumes, surface area,and tissue thickness) represent measured and estimated values
from the literature and were not scaled allometrically. EPISUITE
calculator version 4.10 was used to estimate the mass transfer
coefﬁcients and diffusivity constants [62].3. Results
Model performance evaluation was conducted through compar-
ison to published pharmacokinetic data sets, representing closed
chamber and exhaled breath data, as well as measurements of
BD in the blood and exhaled breath and EB in the blood and lung.
The model simulations were in good agreement with clearance of
various concentrations of BD or EB from closed chambers holding
ﬁve or eight mice [26,37,34] and from chambers holding one or
two rats [4,34] (data not shown).
Themodel simulation of BD inB63CF1mouse or Sprague-Dawley
rat blood during and following six hours of exposure to inhaled BD
[18] was in good agreement with both the mouse data and the rat
data (Fig. 4). While there is a general trend of under-predicting the
post-exposure samples, the model simulation stays within a factor
of 2 of nearly all the measured concentrations. Similar results are
seen with EB, where the model provides good agreement with the
during-exposure measure of EB in plasma but under-predicts the
post-exposure clearance of EB in both mouse and rat (Fig. 5). The
model stays within a factor of 3 for all but the last time-point at
Table 1
Ratio of observed to simulated AUC(120 min-t) for 1,3-butadiene and expoxybutene in
mice and rats exposed nose-only to butadiene for 6 h (observed: [18]).
Ratio AUC(120 min-t)
(Observed:simulated)
Exposure (ppm) Butadiene Epoxybutene
Mouse 62.5 1.04 0.68
625 1.62 0.64
1250 1.00 1.03
Rat 62.5 0.90 1.77
625 1.16 1.02
1250 1.15 1.28
Table A-1
Primary existing models.
Original
publication
Subsequent
published
updates
Notable model features
[27] [28,13] – BD and EB sub-models, with simple dis-
tributed DEB sub-model.
– Saturable metabolism in liver compart-
ment only.
– Intrahepatic ﬁrst-pass metabolism of EB
(to describe the lower-than-expected EB
concentrations in blood).
– Epoxide–GSH conjugation described
with ping–pong kinetics.
[31] [32–34,30] – BD, EB, DEB sub-models.
– Blood compartment divided into arte-
rial, venous, and tissue capillary beds.
– Saturable metabolism in liver, lung, and
kidney.
– Privileged access enzyme channeling
between P450 and epoxide hydrolase
resulting in enhanced hydrolysis of
epoxide metabolites.
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rat at 625 ppm and 1250 ppm. Based upon the ratio of observed
AUC(120 min-t) to that predicted by themodel (Table 1), the ratio stays
well within a factor of 2 of the observed data for both BD and EB in
blood with the highest ratio being 1.62 at 62.5 ppm in the mouse.
The human exhaled concentrations of BD [3] were well-predicted
by the model (Fig. 6).– Epoxide–GSH conjugation described
with bi–bi kinetics.
[40] [5,57–59,26] – BD, EB, DEB sub-models.
– Saturable metabolism in liver and lung.
– Non-enzymatic elimination of EB and
DEB.
– BD metabolism occurs by multiple
enzymes (i.e., EB-producing and
other(s)).
[3] [8,2] – Human lifetime model with 22–41 com-
partments (non-pregnant vs. pregnant).
– First order metabolism in liver, lung, gut,
placenta.
– Pulmonary, fecal, urinary, and lacta-
tional excretion.4. Conclusions
A preliminary PBPK model for BD in mice, rats, and humans has
been developed, which includes regional generation of reactive
metabolites in the lung and metabolism in the kidney, as well as
the hepatic metabolism used in most existing PBPK models of
BD. Previous PBPK models have focused on hepatic metabolism
and systemically circulating reactive metabolites. Here, a PBPK
model has been developed to incorporate species differences in
the distribution of metabolically active club cells throughout the
pulmonary tissues. The complex pulmonary metabolism and addi-
tion of metabolism in the kidney in the model have little impact on
systemic concentrations of BD or EB, but are likely to have a signif-
icant impact on local concentrations of reactive metabolites, as was
observed in the case of styrene [55].
Despite the simplicity of BD’s molecular structure, its metabo-
lism is surprisingly complex, as can be seen from the descriptions
that have been employed in the various PBPK models (Table A-1):
privileged access enzyme channeling between CYP and epoxide
hydrolase, ping–pong, or bi–bi kinetics for glutathione conjugation.
This complexity, plus the reactivity of many of the metabolites, cre-
ates a particular challenge for conducting in vitrometabolism stud-
ies. Similar difﬁculties have been reported for chloroprene [20].
Previous PBPK models of BD have made use of a combination of
in vitro and in vivo data in order to compare the pharmacokinetics
and metabolism of BD between rats and mice. The goal of theFig. 6. Simulation of the 1,3-butadiene concentration in exhaled breath of apresent model, however, is to provide a description of BD pharma-
cokinetics and metabolism in the human. The challenge in devel-
oping a human PBPK model for BD is the lack of in vivo data in
the human. Therefore, we have attempted to avoid reliance on
in vivo data in developing our models for the mouse and rat. In par-
ticular, the metabolic parameters for the mouse and rat were based
to the extent possible on in vitro metabolism data using in vitro to
in vivo extrapolation (IVIVE, [66]), so that the human model could
be similarly developed on the basis of human in vitro metabolism
data. Where it was necessary to use in vivo data to estimate model
parameters in the rat (e.g., to account for privileged access), we
tested our assumptions regarding cross-species parameter equiva-
lence in our extrapolation from the rat to the mouse and thenhuman subject exposed to 5 ppm for 120 min (observed data from [3]).
Table A-2
Physiological parameters.
Parameter Symbol Units Rat Mouse Human Refs.
Minute ventilation rate MVC ml/min 1.909 2.415 3.228 [9]
Cardiac output QCC ml/min 1.756 1.253 1.547 [9]
Fractional blood ﬂow to fat QFC (% QCC) 0.07 0.059 0.052 [9]
Fractional blood ﬂow to liver QLC (% QCC) 0.183 0.161 0.227 [9]
Fractional blood ﬂow to kidney QKC (% QCC) 0.133 0.091 0.175 [34,9]
Fractional blood ﬂow to richly perfused tissues QRC (% QCC) 0.40 0.48 0.43 [9]
Fractional blood ﬂow to nasal tissues QNC (% QCC) 0.001 0.01 0.00247 [21]
Fractional blood ﬂow to conducting airways QCAC (% QCC) 0.021 0.005 0.025 [9]
Fractional blood ﬂow to transitional airways QTAC (% QCC) 0.0015 0.001 0.007 [10]
Body weight BW g 250 25 70,000 [9]
Blood volume VBC (% BW) 0.075 0.049 0.079 [9]
Fat volume VFC (% BW) 0.065 0.070 0.2143 [9]
Liver volume VLC (% BW) 0.037 0.055 0.0257 [9]
Kidney volume VKC (% BW) 0.015 0.0167 0.0044 [34,9]
Slowly perfused tissue volume VPC (% BW) 0.60 0.60 0.5 [9]
Nasal lumen volume VNL Ml 0.25 0.03 9.96 [21]
Conducting airway lumen volume VCAL Ml 1.13 0.11 95.7 [41]
Transitional airway lumen volume VTAL Ml 0.028 0.00087 61 [41]
Fraction of cell volume ﬁlled by ER FACTOR – 0.10 0.10 0.10 Estimated
Surface area of nasal tissues SAN cm2 13.25 2.70 137.7 [21]
Surfaces area of conducting airways SACA cm2 48.30 8.87 2770 [24,44,64]
Surface area of transitional airways SATA cm2 5.50 0.48 6220 [24,44,64]
Surface area of pulmonary region SAPUL cm2 3400 500 540,000 [60]
Mucus thickness WMUC cm 0.001 0.001 0.001 [52]
Nasal tissue thickness WTN cm 0.005 0.005 0.0049 [21]
Conducting airways epithelium thickness WTCA cm 0.0013 0.0013 0.003 [39]
Transitional airway epithelium thickness WTTA cm 0.001 0.001 0.001 [49]
Pulmonary airway epithelium thickness WTPUL cm 0.000038 0.000032 0.000036 [48]
Conducting airway submucosa thickness WXCA cm 0.005 0.005 0.0045 Estimate
Transitional airway submucosa thickness WXTA cm 0.002 0.002 0.002 Estimate
Tissue phase diffusivity constant DIFFTISS cm2/min 0.0002 0.0002 0.0002 [14]
Air phase diffusivity constant DIFFAIR cm2/min 6.42 6.42 6.42 [62]
Table A-3
Biochemical parameters.
Parameter Symbol Units Rat Mouse Human
Blood:air partition coefﬁcient for BD PBBD – 1.95b 1.34a 1.22f
Fat:blood partition coefﬁcient for BD PFBD – 10.8b 14.3a 18.4g
Liver:blood partition coefﬁcient for BD PLBD – 0.595b 1.01a 0.56g
Kidney:blood partition coefﬁcient for BD PKBD – 0.472b 0.472b 0.86g
Poorly perfused tissue:blood partition coefﬁcient for BD PPBD – 0.564b 2.99a 0.72g
Richly perfused tissue:blood partition coefﬁcient for BD PRBD – 0.446b 1.01a 0.56g
Lung:blood partition coefﬁcient for BD PLUBD – 0.615b 1.10a 0.39g
Blood:air partition coefﬁcient for EB PBEB – 56.8b 36.6a 93.3e
Fat:blood partition coefﬁcient for EB PFEB – 2.25b 2.49a 1.8e
Liver:blood partition coefﬁcient for EB PLEB – 0.984b 1.15a 0.59e
Kidney:blood partition coefﬁcient for EB PKEB – 0.842b 0.842b 0.59e
Slowly perfused tissue:blood partition coefﬁcient for EB PPEB – 0.736b 0.64a 0.49e
Richly perfused tissue:blood partition coefﬁcient for EB PREB – 0.908b 1.53a 0.59e
Lung:blood partition coefﬁcient for EB PLUEB – 0.977b 1.53a 0.59e
Fat:blood partition coefﬁcient for BD-diol PFBDIOL – 0.573b 0.573b 0.573b
Liver:blood partition coefﬁcient for BD-diol PLBDIOL – 1.04b 1.04b 1.04b
Kidney:blood partition coefﬁcient for BD-diol PKBDIOL – 0.962b 0.962b 0.962b
Slowly perfused tissue:blood partition coefﬁcient for BD-diol PPBDIOL – 1.139b 1.139b 1.139b
Richly perfused tissue:blood partition coefﬁcient for BD-diol PRBDIOL – 1.22b 1.22b 1.22b
Lung:blood partition coefﬁcient for BD-diol PLUBDIOL – 1.107b 1.107b 1.107b
Gas phase mass transfer coefﬁcient for nasal airways KGN cm/min 20887.0c 21088.0c 277.0c
Gas phase mass transfer coefﬁcient for conducting airway KGCA cm/min 228.0d 312.0d 181.0d
Gas phase mass transfer coefﬁcient for transitional airway KGTA cm/min 481.0d 1136.0d 158.0d
a [58].
b [34].
c [21].
d [14].
e [13].
f [3].
g [17].
J. Campbell et al. / Chemico-Biological Interactions 238 (2015) 102–110 107applied the same assumptions in our extrapolation from the rat to
the human.
Model simulations of exhaled breath in humans (Fig. 6) are gen-
erally similar to observed data, supporting the validity of the IVIVEapproach used to estimate the metabolism parameters in the
model. However, this comparison allows assessment of only the
systemically relevant pharmacokinetic drivers, e.g., partitioning
and total metabolic clearance.
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Several data gaps were identiﬁed during the development of the
present PBPK model; ﬁlling of these data gaps would aid in reﬁne-
ment of a regionally-speciﬁc BD lung model. Metabolic rate con-
stants used in this model were scaled from existing
measurements of whole lung homogenate rather than in single cell
types (club cells) or regional tissue samples. Additionally, while
club cells are the primary metabolically active cells in pulmonary
tissue, Type II cells, alveolar macrophages, and capillary endothe-
lial cells may also be metabolically active, with enzymatic activity
differences of 2- to 20-fold for various enzymes/species (reviewed
brieﬂy by [50]). Metabolic rate constants for downstream BD
metabolites (e.g., BD-diol) also need to be further elucidated in
order to support prediction of the urinary biomarkers identiﬁedTable A-4
Metabolic rate constants for the 1,3-butadiene PBsPK model.
Parameter Symbol
Max metabolic rate for CYP-mediated BD? EB in the liver VMAXCYPL
Max metabolic rate for CYP-mediated BD? EB in the lung VMAXCYPLU
Max metabolic rate for CYP-mediated BD? EB in the kidney VMAXCYPK
Max conjugation rate for EB? EB-GSH in liver VMAXGSHL
Max Conjugation Rate for EB? EB–GSH in lung VMAXGSHLU
Max conjugation rate for EB? EB–GSH in kidney VMAXGSHK
Max hydrolyzation rate for EB? BD-diol in liver VMAXEHL
Max hydrolyzation rate for EB? BD-diol in lung VMAXEHLU
Max hydrolyzation rate for EB? BD-diol in kidney VMAXEHK
Max metabolic rate for CYP-mediated EB? DEB in the liver VMAXEBCYPL
Max metabolic rate for CYP-mediated EB? DEB in Clara cells VMAXEBCYPLU
Max metabolic rate for CYP-mediated EB? DEB in kidney VMAXEBCYPK
Max metabolic rate for CYP-mediated BDIOL in the liver MAXCYPBDIOL
Max metabolic rate for CYP-mediated BDIOL in the lung MAXCYPBDIOL
Max metabolic rate for CYP-mediated BDIOL in the kidney MAXCYPBDIOK
Afﬁnity constant for CYP-mediated BD? EB in lung KMCYP
Afﬁnity constant for CYP-mediated BD? EB in liver KMCYPL
Afﬁnity constant for CYP-mediated BD? EB in kidney KMCYPK
Afﬁnity constant for CYP-mediated EB? DEB KMEBCYP
Afﬁnity constant for CYP-mediated EB? DEB in liver KMEBCYPL
Afﬁnity constant for CYP-mediated EB? DEB in kidney KMEBCYPK
Afﬁnity constant for EH-med. EB? BD-diol KMEH
Afﬁnity constant for EH-med. EB? BD-diol in liver KMEHL
Afﬁnity constant for EH-med. EB? BD-diol in kidney KMEHK
Afﬁnity constant for GSH conjugation, GST–GSH KMGSH
Afﬁnity constant for GSH conjugation, GST–EB in the liver KMEBL
Afﬁnity constant for GSH conjugation, GST–EB in the lung KMEBLU
Afﬁnity constant for GSH conjugation, GST–EB in the kidney KMEBK
Basal degradation rate for GSH KEGSH
Initial GSH concentration in liver CGSHL0
Initial GSH concentration in richly perfused tissues CGSHR0
Initial GSH concentration in conducting airway tissue CGSHCA0
Initial GSH concentration in transitional airway tissue CGSHTA0
Initial GSH concentration in pulmonary tissue CGSHP0
Initial GSH concentration in kidney tissue CGSHK0
Release of EB from privileged access KRELEB
Microsomal protein content in liver MMPPGL
Microsomal protein content in lung MMPPGLU
Microsomal protein content in kidney MMPPGK
Cytosolic protein content in liver MCPPGL
Cytosolic protein content in lung MCPPGLU
Cytosolic protein content in kidney MCPPGK
a [27].
b [12].
c [59].
d Set to liver.
e [34].
f Seaton et al. [56].
g [53].
h [22].
i Yoon et al. [65].
j Set to rat value.
k Set to lung.
l [54].
m Estimated to minimize ratio of model to measured plasma EB AUC in rat.in the literature. Time-course information on BD metabolite con-
centration proﬁles in rodent and human urine could then be used
to reﬁne the parameterization and to evaluate model predictions of
BD and metabolite dosimetry for long-term exposures.Conﬂict of Interest
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nmol/min/mg protein 2.17a 2.59b 0.23c
nmol/min/mg protein 0.16b 2.31b 0.15b
nmol/min/mg protein 0.21b 2.31b 0.15d
nmol/min/mg protein 241b 500b 45.1b
nmol/min/mg protein 44.2b 273b 8.3b
nmol/min/mg protein 44.2b 273b 8.3b
nmol/min/mg protein 17.0a 19.0a 3.1c
nmol/min/mg protein 0.71e 0.58e 3.1d
nmol/min/mg protein 0.25e 1.88e 3.1d
nmol/min/mg protein 0.41f 1.3f 0.915c
nmol/min/mg protein 0.41d 1.3d 0.164e
nmol/min/mg protein 0.41d 1.3d 0.21e
L nmol/min/mg protein 1.12e 0.27e 3.1c
LU nmol/min/mg protein 0.53e 0.02e 3.1d
nmol/min/mg protein 1.42e 0.02e 3.1d
nmol/ml 3.75b 5.0b 0.7j
nmol/ml 7.75b 2.0b 0.7b
nmol/ml 7.75 5.0d 0.7j
nmol/ml 15.6b 15.6b 880e
nmol/ml 15.6d 15.6d 880k
nmol/ml 15.6d 15.6d 880k
nmol/ml 140a 300a 540c
nmol/ml 140d 300d 540k
nmol/ml 140d 300d 540k
nmol/ml 100a 100a 100j
nmol/ml 13,800b 35,300b 10,400b
nmol/ml 17,400b 36,500b 10,400d
nmol/ml 13,800d 35,300d 10,400d
1/min 0.0025a 0.0048a 0.012c
nmol/ml 6120.0b 8300.0b 6000.0c
nmol/ml 2000.0e 2000.0j 2000.0j
nmol/ml 1580.0g 1580.0j 1580.0j
nmol/ml 1580.0g 1580.0j 1580.0j
nmol/ml 1580.0g 1580.0j 1580.0j
nmol/ml 2240.0g 2240.0j 2240.0j
1/min 1.4m 1.4j 1.4j
mg/g 45.0h 45.0j 40.0g
mg/g 7.7i 7.7d 2.27l
mg/g 7.7k 7.7d 2.27k
mg/g 91.0g 91.0j 80.7g
mg/g 38.0h 38.0j 38.0j
mg/g 38.0k 38.0j 38.0j
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